Intestinal smooth muscle signaling

Intestinal smooth muscle signaling is a complex physiological process that coordinates the contraction and relaxation of smooth muscle cells in the gut to facilitate digestion and peristalsis (StatPearls, NBK526124). This signaling network integrates inputs from the enteric nervous system, autonomic nervous system, and interstitial cells of Cajal, involving key molecular players such as muscarinic M3 receptors, L-type voltage-gated calcium channels, and intracellular enzymes like myosin light chain kinase (MLCK) (PubMed, PMID: 15556821). Activation of these pathways leads to an increase in intracellular calcium and subsequent cross-bridge cycling, facilitating peristalsis and the movement of luminal contents. Conversely, relaxation is often mediated by nitric oxide or vasoactive intestinal peptide (VIP) through cyclic nucleotide pathways that activate myosin light chain phosphatase (KEGG, map04270). Dysregulation of this signaling is central to various motility disorders, including irritable bowel syndrome (IBS), gastroparesis, and chronic intestinal pseudo-obstruction. Pharmacological intervention typically targets specific components of this signaling cascade, such as using antispasmodics to inhibit muscarinic receptors or prokinetics to stimulate serotonin receptors, thereby restoring normal gut motility (PubChem, CID 3001).

Other names

Gastrointestinal smooth muscle signalingGI smooth muscle contraction pathwayIntestinal motility signaling

Drugs modulate this signaling pathway by acting as antagonists at muscarinic receptors to reduce contraction, blocking L-type calcium channels to induce relaxation, or acting as agonists at serotonin receptors to enhance motility and peristalsis.